SUMMARY

• RYBREVANT (amivantamab-vmjw) is administered in combination with carboplatin and pemetrexed intravenously (IV) weekly (QW) for 4 weeks, with the initial dose as a split infusion in Week 1 on Day 1 and Day 2, then every 3 weeks starting at Week 7 until disease progression or unacceptable toxicity. When administering RYBREVANT in combination with carboplatin and pemetrexed, infuse pemetrexed first, carboplatin second, and RYBREVANT last.¹
• RYBREVANT is administered in combination with LAZCLUZE (lazertinib) or as a single agent IV QW for 5 weeks, with the initial dose as a split infusion in Week 1 on Day 1 and Day 2, then every 2 weeks starting at Week 7 until disease progression or unacceptable toxicity. When administering RYBREVANT in combination with LAZCLUZE, administer LAZCLUZE orally any time before the RYBREVANT infusion.¹
• Administer premedications before each RYBREVANT infusion as recommended. Monitor patients for any signs and symptoms of infusion reactions during RYBREVANT infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.¹
• RYBREVANT administration was permitted in outpatient settings per the clinical trial protocol for the phase 1 CHRYSALIS study.²
• Please refer to the DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS sections of the full Prescribing Information.¹

PRODUCT LABELING

• RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
• LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 29 April 2025.